Market Signal Briefing

March 09, 2026 07:05 ET  | Source: Bitfarms Ltd.

TORONTO and NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, today announced a series of strategic hires across its infrastructure and corporate teams. These additions bring deep expertise in power development, large‑scale construction, permitting, and corporate scaling as Bitfarms accelerates build‑outs across its portfolio.

“We are excited to welcome Tara, Michael, Christopher, Paul, Kevin, and Tom to our leadership team,” said CEO Ben Gagnon. “As we continue toward U.S. domiciliation and advance our sites, building a seasoned domestic leadership bench is essential. Our recent hires bring substantial industry experience, with an average of more than 20 years in digital and power infrastructure and extensive backgrounds in complex construction and specialized HPC data center development. Our new leaders will be based out of our New York office, positioning us to operate with greater coordination and focus as we enter the next phase of our growth.”

Infrastructure Leadership Strengthened to Advance HPC/AI Development

Michael Byrne joins as Senior Vice President of Construction. Michael brings a decade of hyperscale data center project delivery experience across North America, South America and Europe. Michael’s career includes leadership roles at Linesight and Aurecon where he oversaw significant hyperscale development programs, leading program management, multi‑region execution, commercial governance, contractor oversight, and lifecycle delivery from concept through commissioning. At Bitfarms, he will lead end‑to‑end construction execution for our HPC/AI data center development portfolio, applying his proven ability to manage megaproject portfolios.

Christopher Ruppel joins as Senior Vice President of Power. Chris brings more than two decades of experience bridging advanced compute infrastructure with energy systems optimization. Chris has led development strategies spanning onsite power, grid‑connected assets, and gas‑to‑power solutions for high‑density AI and edge‑compute environments. His track record includes originating and developing 4 GW of energy projects globally, structuring billions of dollars in project financings, and advising data center operators on resilient, commercially optimized energy strategies. Chris joins Bitfarms from MARA Holdings, where he served as Head of Energy Development. At MARA, he led the strategy for the Digital Energy division, focusing on behind-the-meter power, thermal strategies, and demand-response initiatives.

Paul Peterson joins Bitfarms as Vice President of HPC Operations. Paul brings nearly two decades of deep expertise in data centers, critical environments, and engineering services and operations. His career includes senior leadership roles at JLL Global and CBRE, where he oversaw large‑scale engineering projects, guided complex infrastructure strategies, advanced global assessment and compliance programs, and drove operational excellence for enterprise, colocation, and hyperscale clients. With a foundation that spans hands‑on engineering, facility management, auditing, and strategic technical leadership, Paul has repeatedly served as a trusted advisor to stakeholders—translating technical risk into business impact, strengthening reliability programs, and shaping industry‑leading standards.

Kevin Roberts joins Bitfarms as Director of Permitting. Kevin has over two decades of experience as a senior project development, environmental and regulatory leader across energy infrastructure, utilities, and hyperscale data centers. He has directed multi-million development portfolios and led permitting and compliance for over 50 natural gas facilities, more than 1,000 miles of pipeline, and multiple utility‑scale data center developments across the United States. In his role at Bitfarms, he will utilize his expertise in environmental compliance, site selection, utilities coordination, and multidisciplinary project management to ensure Bitfarms’ HPC/AI campuses progress efficiently through federal, state, and local approval processes.

Key Additions to Corporate Leadership

Tara Goldstein has been appointed Senior Vice President of Marketing. Tara is responsible for building and leading Bitfarms’ global marketing and communications function, overseeing brand strategy, corporate narrative, digital presence, and enterprise-wide positioning. Tara has over two decades of experience leading strategy, storytelling, and placemaking for high-profile real estate and technology-driven companies. Before leading a full-service creative agency, she served as Senior Vice President of Marketing at Brookfield Properties, overseeing marketing for their 98-million-square-foot global office, retail, and residential portfolio. During her tenure, she led the rebrand and repositioning of Brookfield Place New York, the multi-phased Manhattan West development, and numerous other award-winning initiatives.

Thomas Tyree III has been appointed Senior Vice President, Finance & Strategy at Bitfarms. Tom leads financial and strategic initiatives supporting Bitfarms’ HPC/AI transition, including capital markets activities, capital allocation, and strategic partnerships. He brings extensive experience in corporate finance, financial analysis, and execution of complex transactions across energy, power, and infrastructure. Prior to Bitfarms, Tom was a member of the executive leadership team at Stronghold Digital Mining, where he led the company’s initial public offering, several structured financings, and the strategic review process that led to Stronghold’s sale to Bitfarms. Before Stronghold, Tom worked at Riverstone Holdings, a $40 billion asset-management firm focused on energy, power, and infrastructure investments.

About Bitfarms Ltd.

Bitfarms is a North American digital infrastructure and energy company that develops, owns, and operates data centers and energy infrastructure for high-performance computing and next-generation-technology applications, including artificial intelligence.

Bitfarms’ 2.1 GW North American energy portfolio is comprised of energized, under development, and pipeline MW, located in established data center clusters, with robust access to power and fiber infrastructure.

Bitfarms is headquartered in New York, NY and Toronto, ON and traded on the Nasdaq and the Toronto Stock Exchange.

To learn more about Bitfarms’ events, developments, and online communities:
www.bitfarms.com
http://x.com/Bitfarms_io
https://www.linkedin.com/company/bitfarms/

Forward-Looking Statements  
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. The statements and information in this release regarding the strategic hires to support HPC/AI infrastructure development and the anticipated contributions of new leadership and other statements regarding future growth, plans and objectives of Bitfarms are forward-looking information.

Any statements that involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “prospects”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. This forward-looking information is based on assumptions and estimates of management of Bitfarms at the time they were made, and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Bitfarms to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors, risks and uncertainties include, among others: the anticipated benefits of the U.S. redomiciliation, and the anticipated rebalancing of operations to North America and from Bitcoin mining to digital infrastructure may occur on a timeline different than the expectations of Bitfarms, may not occur at all, and may have unanticipated costs for Bitfarms; the anticipated benefits of the rebalancing of operations to North America and the North American energy and compute infrastructure strategy may not be realized or the realization of such benefits may be delayed; an inability to apply Bitfarms’ data centers to HPC/AI opportunities on a profitable basis; a failure to secure long-term contracts associated with HPC/AI customers on terms which are economic or at all; the construction and operation of new facilities may not occur as currently planned, or at all; expansion of existing facilities may not materialize as currently anticipated, or at all; the construction and operation of new facilities may not occur as currently planned, or at all; expansion of existing facilities may not materialize as currently anticipated, or at all; failure of the equipment upgrades to be installed and operated as planned; the availability of additional power may not occur as currently planned, or at all; expansion may not materialize as currently anticipated, or at all; the power purchase agreements and economics thereof may not be as advantageous as expected the risks of an increase in electricity costs, cost of natural gas, changes in currency exchange rates, energy curtailment or regulatory changes in the energy regimes in the jurisdictions in which Bitfarms operates and the potential adverse impact on profitability; future capital needs and the ability to complete current and future financings, as well as capital market conditions in general; share dilution resulting from equity issuances; and the adoption or expansion of any regulation or law that will prevent Bitfarms from operating its business, or make it more costly to do so. For further information concerning these and other risks and uncertainties, refer to Bitfarms’ filings on www.sedarplus.ca (which are also available on the website of the U.S. Securities and Exchange Commission at www.sec.gov), including Bitfarms’ annual information form for the year ended December 31, 2024, management’s discussion & analysis for the year-ended December 31, 2024 and the management’s discussion and analysis for the three and nine months ended September 30, 2025. Although Bitfarms has attempted to identify important factors that could cause actual results to differ materially from those expressed in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended, including factors that are currently unknown to or deemed immaterial by Bitfarms. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on any forward-looking information. Bitfarms does not undertake any obligation to revise or update any forward-looking information other than as required by law. Trading in the securities of Bitfarms should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the Toronto Stock Exchange, Nasdaq, or any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A 

Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H’28

Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H’26

Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26; update on indication prioritization planned for 1H’26

$514.4 million of cash as of December 31, 2025 provides runway into 2028

Investor conference call and webcast to be held to discuss the CAPTIVATE trial interim responder analysis today, March 9, 2026 at 8:00 a.m. ET 

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2025, announced a GO decision in the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and provided an update on other recent business achievements.

“It is truly exciting to be part of a company developing potential best-in-disease therapies for patients suffering from severe autoimmune diseases. I am very proud of the impressive level of execution the Dianthus team continues to deliver against our ambitious goals,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “With claseprubart, we are building a leading neuromuscular franchise with a target product profile that aims to combine best-in-class efficacy and safety with the convenience of an infrequent, subcutaneous, self-administered autoinjector that has the potential to meaningfully shift the treatment paradigm and standard of care for more than 150,000 patients in the U.S. living with gMG, CIDP and MMN.”

Claseprubart (DNTH103) Clinical Development

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.

Generalized Myasthenia Gravis (gMG)

Phase 3 trial expected to initiate mid-2026, with top-line results expected in 2H’28: Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is expected to initiate in mid-2026, with top-line results expected in 2H’28.
Claseprubart data presented at Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, March 8-11, 2026: Three poster presentations describing claseprubart Phase 2 MaGic results and in vitro data are available on the Investors section of the Dianthus website under Scientific Publications. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Early GO decision announced in Phase 3 CAPTIVATE trial: The target for the Part A interim responder analysis was a response rate of 50% or greater (i.e., ≥20 confirmed responders out of first 40 participants to complete Part A) based on precedent set with aC1s inhibition. This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing open-label Part A of the trial. Dianthus expects to provide CAPTIVATE Part B top-line guidance by YE’26. Multifocal Motor Neuropathy (MMN)

Phase 2 MoMeNtum MMN trial remains on track for top-line results in 2H’26: The MoMeNtum trial is an ongoing global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN. DNTH212 Clinical Development

DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.

Phase 1 data anticipated in 2H’26: A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) was initiated in December 2025, with top-line results in healthy volunteers expected in 2H’26. An update on indication prioritization for DNTH212 is planned for 1H’26. Full Year 2025 Financial Results

Cash Position – $514.4 million of cash, cash equivalents and investments as of December 31, 2025 is projected to provide runway into 2028. R&D Expenses – Research and development (R&D) expenses for the year ended December 31, 2025 were $145.6 million, inclusive of $10.1 million of stock-based compensation, compared to $83.1 million for the year ended December 31, 2024, which included $5.6 million of stock-based compensation. This increase in R&D expenses was primarily driven by higher clinical costs, upfront and clinical development milestones for DNTH212, and increased headcount to support claseprubart Phase 2 and Phase 3 development.G&A Expenses – General and administrative (G&A) expenses for the year ended December 31, 2025 totaled $34.3 million, inclusive of stock-based compensation of $12.7 million, compared to $25.0 million for the year ended December 31, 2024, which included $7.3 million of stock-based compensation. This increase in G&A expenses was primarily due to increased headcount.Net Loss – Net loss for the year ended December 31, 2025 was $162.3 million or $4.20 per share (basic and diluted) compared to $85.0 million or $2.55 per share (basic and diluted) for the year ended December 31, 2024.Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2025, please refer to the Form 10-K filed with the SEC. CAPTIVATE Investor Conference Call & Webcast to be Held at 8:00 a.m. ET Today
Dianthus Therapeutics will host an investor call and webcast to discuss the CAPTIVATE interim responder analysis today, March 9, 2026 at 8:00 a.m. ET. To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. 

The live webcast may be accessed via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/. A replay of the webcast will be available following the call. The presentation that will be used on this webcast is available here.

About Claseprubart (DNTH103)
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with claseprubart and expects to initiate a Phase 3 trial in generalized Myasthenia Gravis in mid-2026, with top-line results expected in 2H’28, report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in 2H’26, and provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE’26.

Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

About DNTH212
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) is ongoing, with top-line results in healthy volunteers expected in 2H’26.

DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart and DNTH212, and any developments or results in connection therewith, including the target product profile and administration of claseprubart and DNTH212; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential opportunities for complement therapies, in particular with respect to claseprubart and DNTH212. Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart or DNTH212 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
[email protected]

 DIANTHUS THERAPEUTICS, INC.
Consolidated Balance Sheets
(unaudited, in thousands)      December 31,   2025  2024 Assets      Current assets:      Cash and cash equivalents $51,087  $22,792 Short-term investments  353,208   252,449 Receivable from former related party  —   807 Accounts receivable, net  52   — Prepaid expenses and other current assets  5,091   4,856 Total current assets  409,438   280,904 Long-term investments  110,135   81,728 Property and equipment, net  296   194 Right-of-use operating lease assets  1,337   1,553 Other assets and restricted cash  9,716   9,629 Total assets $530,922  $374,008 Liabilities and Stockholders’ Equity      Current liabilities:      Accounts payable $9,725  $4,579 Accrued expenses  19,452   13,074 Current portion of deferred revenue  1,188   479 Current portion of operating lease liabilities  367   320 Total current liabilities  30,732   18,452 Deferred revenue  5,770   1,908 Long-term operating lease liabilities  1,019   1,171 Total liabilities  37,521   21,531 Commitments and contingencies      Stockholders’ equity:      Preferred stock  —   — Common stock  43   31 Additional paid-in capital  829,598   526,732 Accumulated deficit  (336,729)  (174,392)Accumulated other comprehensive income  489   106 Total stockholders’ equity  493,401   352,477 Total liabilities and stockholders’ equity $530,922  $374,008           Dianthus Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(unaudited, in thousands, except share and per share data)
         Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024Revenues:       License revenue – related party$    —  $999  $      —  $5,909 License revenue 284   326   2,036   326 Total revenues 284   1,325   2,036   6,235         Operating expenses:       Research and development 59,895   26,413   145,638   83,105 General and administrative 9,930   6,828   34,331   24,994 Total operating expenses 69,825   33,241   179,969   108,099         Loss from operations (69,541)  (31,916)  (177,933)  (101,864)        Other income/(expense):       Interest and investment income 5,267   3,991   16,119   17,365 Gain/(loss) on investment in related party 254   (160)  508   148 Gain/(loss) on currency exchange, net (3)  27   (57)  (64)Other expense (409)  (380)  (974)  (554)Total other income 5,109   3,478   15,596   16,895         Net loss$(64,432) $(28,438) $(162,337) $(84,969)        Net loss per share attributable to common stockholders, basic and diluted$(1.43) $(0.81) $   (4.20) $(2.55)        Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted             
44,971,383               
35,033,773   38,617,580   33,313,849         Comprehensive loss:       Net Loss$(64,432) $(28,438) $   (162,337) $(84,969)Other comprehensive income/(loss):       Unrealized gain/(loss) on marketable securities 326   (575)  383   59 Total other comprehensive income/(loss) 326   (575)  383   59 Total comprehensive loss$(64,106) $(29,013) $   (161,954) $(84,910)                

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, you are encouraged to visit https://grabarlaw.com/the-latest/category/current-investigations/, contact Joshua Grabar at [email protected], or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action. Please contact Joshua Grabar at [email protected], or call us at 267-507-6085 to learn more.

WHY? According to a recently filed federal securities fraud class action lawsuit, Nektar Therapeutics (NASDAQ: NKTR), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On December 16, 2025, Nektar issued a press release "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator." The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

WHAT CAN YOU DO NOW? If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, and still hold shares today, please visit https://grabarlaw.com/the-latest/category/current-investigations/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action.

#NKTR $NKTR #Nektar

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287739

Source: Grabar Law Office

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

As investors navigate an increasingly complex market, the demand for sophisticated, outcome-oriented ETF strategies has reached a significant inflection point. Goldman Sachs Asset Management is seeing strong success in this space, evolving its suite of derivative-based ETFs to meet the diverse needs of modern portfolios.

The Rise of Premium Income: GPIX and GPIQ A primary driver of the firm’s recent momentum has been the performance and adoption of its premium income products, specifically the Goldman Sachs S&P 500 Core Premium Income ETF (GPIX) and the Goldman Sachs Nasdaq-100 Core Premium Income ETF (GPIQ). According to Brendan McCarthy, Head of ETF Distribution at Goldman Sachs, the success of these products is driving the firm’s conviction to “pursue more opportunities in the options space.”

These ETFs are playing a vital role in portfolio construction, acting as a “core-plus” allocation that allows investors to maintain market participation while generating monthly cash flow. Rather than replacing core large-cap equity exposure, GPIX and GPIQ can complement it by smoothing out volatility and providing a defensive income cushion during sideways or slightly bearish markets. GPIX and GPIQ each added more than $500 million in the first two months of 2026 to push assets for both over $3 billion.

McCarthy notes that the category is seeing impressive year-to-date flows as clients seek different flavors of income, including those that combine index-based and active components. Goldman is likely looking to expand their lineup of equity income strategies to other investment styles, such as small-cap and international equities.

Talking Defined Outcome ETFs at Exchange The conversation around derivative-based strategies is set to accelerate at the Exchange conference, where Bryon Lake of Goldman Sachs will take the stage with Bruce Bond of Innovator Capital. The duo will discuss with Bloomberg’s Katie Greifeld the growing role of defined outcome ETFs—a category McCarthy describes as “incredibly relevant in today’s marketplace.” Goldman Sachs announced a pending acquisition of Innovator Capital in 2025 that is expected to close by the end of the first half of 2026.

Innovation Beyond Income: Private Equity Replication Goldman is also making strides in the alternative ETFs space through a partnership with MSCI. The Goldman Sachs MSCI World Private Equity Return Tracker ETF (GTPE) launched in October 2025.  By creating a private equity return tracker index, the firm offers a liquid ETF wrapper that replicates the characteristics of private equity using public equities and quantitative strategies. McCarthy explained GTPE provides a functional tool for institutional investors managing liquidity during capital calls as well as allows retail investors to incorporate alternative sleeves into their model portfolios.

For more news, information, and analysis, visit VettaFi | ETF Trends. 

Earn free CE credits and discover new strategies

HomeDividends AnalysisREITs AnalysisReal Estate Analysis

SummaryWelltower is booming on strong senior housing demand.But it trades at one of the highest valuations in the REIT sector.If growth slows, the downside could be significant.High Yield Landlord members get exclusive access to our real-world portfolio. See all our investments here » Zolak/iStock via Getty Images

Welltower (WELL) is one of the most popular REITs in the entire world, and it is simple to understand why.

It is the biggest REIT in the world with a massive $142 billion market cap, providing enormous

69.01K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ARE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeMarket OutlookToday's Market

SummaryThe U.S.-Iran conflict has severely disrupted oil flows through the Strait of Hormuz, triggering production cuts and storage constraints across Gulf states.Oil futures spiked 15%, hitting $100, but extreme volatility and risk make oil futures and ETFs unattractive at current levels.I maintain a long position in gold via GDMN and GLTR ETFs, viewing precious metals as a hedge against ongoing geopolitical instability despite the sell-off at the onset of war.Investors should reassess risk tolerance and prioritize prudent position sizing in this environment of heightened uncertainty.AJ_Watt/E+ via Getty Images

As we head into the second week of the U.S.-Iran War, one thing is becoming clear: there is no easy way out. The status of the Strait of Hormuz, which I believe is the key to ensuring the U.S. and its

9.19K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GDMN, GLTR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK--(BUSINESS WIRE)--American Strategic Investment Co. (NYSE: NYC) (“ASIC” or the “Company”) announced today it will release its financial results as of, and for the fourth quarter and year ended December 31, 2025, on Thursday March 26, 2026, before the New York Stock Exchange open. The Company will also host a webcast and conference call the same day at 11:00 a.m. ET to review results and provide commentary on business performance. Dial-in instructions for the conference call and the rep.

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approved dosing regimen remains 1mg/kg every 2 weeks. Please see Important Safety Information below and the Full Prescribing Information, including Boxed Warning.

European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT)

With this decision, announced ahead of Fabry Disease Awareness Month in April, Chiesi Global Rare Diseases will work with countries across the EU to support broader access to this additional dosing schedule for the adult Fabry community

PARMA, Italy and CARMIEL, Israel, March 09, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that the European Commission (EC) has approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® (pegunigalsidase alfa) in adults living with Fabry disease who are stable with an ERT. The EC decision follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the additional dosing regimen.

“The European Commission approval for 2mg/kg body weight E4W dosing regimen for pegunigalsidase alfa represents a meaningful advancement for adults living with Fabry disease and their families,” said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. “Because Fabry disease requires lifelong treatment, the cadence of therapy inevitably becomes part of everyday life for patients and caregivers. By introducing an option that extends the infusion interval from every two weeks to every four weeks for eligible patients on stable ERT, we are offering families greater flexibility and the possibility to ease the overall burden of treatment. Ultimately, our goal is simple but profound: to help people spend less time managing their disease and more time living their lives. This milestone reflects our commitment to innovation that goes beyond delivering therapies—by listening to and understanding the real experiences of the Fabry community.”

“In Fabry disease, long-term treatment decisions must balance disease management with the realities of lifelong therapy,” said Prof. Aleš Linhart, DrSc, FESC. “The approval of pegunigalsidase alfa 2mg/kg every-4-weeks provides an additional option that may help reduce cumulative treatment burden for appropriate patients while maintaining continuity of care.”

“This approval strengthens the treatment landscape for Fabry disease across the European Union by introducing an additional dosing approach that has the potential to enhance long-term care,” said Dror Bashan, President and Chief Executive Officer, Protalix BioTherapeutics. “The authorization reflects not only scientific progress, but also a commitment to optimizing care delivery in a way that supports both patients and healthcare systems.”

“For many people living with Fabry disease, treatment is a lifelong commitment that impacts nearly every aspect of daily life,” said Mary Pavlou, President, Fabry International Network (FIN). “This approval allows for fewer infusion visits, helping reduce the ongoing burden on patients and families, allowing them to spend more time living their lives beyond treatment.”

The EC approval is informed by results from an open-label, switch-over study, BRIGHT (formally PB-102-F50), designed to assess the adverse-event profile, efficacy, and pharmacokinetics (PK) of the alternative dosing regimen of pegunigalsidase alfa 2-mg/kg E4W for 52 weeks,1 and its ongoing open-label extension study CLI-06657AA1-03 (formerly PB-102-F51).2

Protalix is entitled to a regulatory milestone payment of $25 million from Chiesi in connection with the EC’s approval of the E4W dosing regimen.

This EU approval does not change the FDA‑approved dosing regimen, which remains 1-mg/kg every 2 weeks. Please consult with your healthcare provider.

About Elfabrio®
Elfabrio (pegunigalsidase alfa-iwxj), a PEGylated enzyme replacement therapy (ERT) to treat Fabry disease, is a plant cell culture-expressed, and chemically modified stabilized recombinant version of the α-‑Galactosidase-‑A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with stable pharmacokinetic parameters. In clinical studies, Elfabrio has been observed to have an initial half-life of 78.9 ± 10.3 hours.

Indication and Important Safety Information

Indication
Elfabrio® (pegunigalsidase alfa-iwxj) is indicated for the treatment of adults with confirmed Fabry disease.

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXISPatients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Elfabrio administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue Elfabrio immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Elfabrio may be considered.

Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and infusion-associated reactions (IARs), and instruct them to seek medical care immediately if such symptoms occur.

If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Elfabrio administration and initiate appropriate medical treatment.If a mild to moderate hypersensitivity reaction or IAR occurs, consider slowing the infusion rate or temporarily withholding the dose. In clinical trials, 20 (14%) Elfabrio-treated patients experienced hypersensitivity reactions. Four Elfabrio-treated patients (3%) experienced anaphylaxis reactions that occurred within 5 to 40 minutes of the start of the initial infusion. The signs and symptoms of hypersensitivity reactions and anaphylaxis included headache, nausea, vomiting, throat tightness, facial and oral edema, truncal rash, tachycardia, hypotension, rigors, urticaria, intense pruritus, moderate upper airway obstructions, macroglossia, and mild lip edema.

In clinical trials, 41 (29%) Elfabrio-treated patients experienced one or more infusion-associated reactions, including hypersensitivity, nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension.

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If glomerulonephritis is suspected, discontinue treatment until a diagnostic evaluation can be conducted.

When switching to Elfabrio from a prior enzyme replacement therapy, the risk of hypersensitivity reactions and infusion-associated reactions may be increased in certain patients with pre-existing anti-drug antibodies (ADAs). Consider monitoring IgG and IgE ADAs and clinical or pharmacodynamic response (eg, plasma lyso-Gb3 levels).

The most common adverse reactions (≥15%) were infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.

Please see Full Prescribing Information for Elfabrio including Boxed Warning, for Elfabrio®

About Fabry Disease
Fabry disease is a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene, which leads to a deficiency of the enzyme alpha-galactosidase A. This deficiency results in an accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body’s cells, affecting the heart, kidneys, skin, nervous system, and other organs.3 Fabry disease can cause a range of serious signs and symptoms, including fatigue, chronic pain, gastrointestinal issues, decreased ability to sweat, progressive kidney failure, heart complications, and increased risk of stroke.4

The condition affects both males and females and can present from childhood through adulthood, often with delayed diagnosis or misdiagnosis. While Fabry disease is rare, early detection and access to appropriate treatment — such as enzyme replacement therapy or pharmacological chaperones therapy — are critical in managing symptoms and slowing disease progression.3

About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For more information visit www.chiesi.com.

About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.

For more information visit www.chiesirarediseases.com.

And Follow @ChiesiGlobalRareDiseases on LinkedIn, Facebook, Instagram and X

About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix’ s proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain US Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil, where Protalix retains full rights. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of pegunigalsidase alfa, which was approved by both the FDA and the EMA in May 2023. Protalix’ s development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; To learn more, please visit www.protalix.com.

Protalix BioTherapeutics, Inc. Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “anticipate,” “believe,” “estimate,” “expect,” “can,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: the risk that the EC will not approve the CHMP’s positive opinion recommending approval of the 2mg/kg every-4-weeks (E4W) dosing regimen for pegunigalsidase alfa in adults with Fabry disease; risks related to the commercialization of pegunigalsidase alfa; risks relating to pegunigalsidase alfa market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; delays in the approval or potential rejection of any applications filed with the FDA, EMA or other health regulatory authorities for Protalix' s product candidates, and other risks relating to the review process; the risk that the results of clinical trials will not support the applicable claims of safety or efficacy; ; risks relating to changes to published interim, topline or preliminary data from clinical trials; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; and risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and other factors described in our filings with the US Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and Protalix disclaims any obligation to update this information, except as may be required by law.

Chiesi Global Rare Diseases Media Contact
Sky Striar
LifeSci Communications
Email: [email protected]

Protalix BioTherapeutics, Inc. Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
[email protected]

References
1)   Holida, M, et al., (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme. Journal of Inherited Metabolic Disease. doi:10.1002/jimd.12795.

2)   Bernat et al., (2025). Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: five-year interim results from the ongoing BRIGHT51 study Abstract presented at ICIEM Congress 2025.

3)   Mehta, A., & Hughes, D. A. (2024). Fabry disease. In M. P. Adam, S. Bick, G. M. Mirzaa, et al. (Eds.), GeneReviews®. University of Washington, Seattle.

4)   Cleveland Clinic. (2025, October 9). Fabry disease: Symptoms & causes.

CHICO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU), the women’s clothing brand offering modern, feminine styles at accessible prices for every occasion, announced today that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 30, 2026, after market close. The Company will host a conference call and live webcast with the investment community at 5:00 p.m. Eastern Time that same day.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.lulus.com/. To access the call through a conference line, dial 1-877-407-0792 (in the U.S.) or 1-201-689-8263 (international callers).

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1-844-512-2921 (in the U.S.) or 1-412-317-6671 (international callers). The access code for the replay is 13758896.

About Lulus

Headquartered in California, but serving millions of customers worldwide, Lulus is a women’s clothing brand offering modern, feminine styles at accessible prices for every occasion. Our goal is to make every customer feel their most confident and beautiful for the moments that matter most. Founded in 1996 and delivering fresh styles almost every day, Lulus uses direct customer feedback and insights to refine product offerings and elevate the customer experience. Lulus’ world-class personal stylists, bridal concierge, and customer care team provide thoughtful, personalized service to shoppers around the world. Follow @lulus on Instagram and @lulus on TikTok. Lulus is a registered trademark of Lulu’s Fashion Lounge, LLC. All rights reserved.

Contact

Corporate Communications
[email protected]

, /PRNewswire/ -- Zeta Network Group ("Zeta" or the "Company") (Nasdaq: ZNB), today announced that the Company's board of directors approved on February 10, 2026, that the authorised, issued, and outstanding shares of the Company be consolidated on a 100 for 1 ratio with the marketplace effective date of March 12, 2026.

The objective of the share consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq.

Beginning with the opening of trading on March 12, 2026, the Company's Class A ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol "ZNB" but under a new CUSIP number, G2287A142.

As a result of the share consolidation, each 100 Class A ordinary shares outstanding will automatically combine and convert to one issued and outstanding Class A ordinary share without any action on the part of the shareholders. No fractional shares will be issued to any shareholders in connection with the share consolidation, and each shareholder will be entitled to receive one share of the Company in lieu of the fractional share of that class that would have resulted from the share consolidation.

At the time the share consolidation is effective, the Company's authorized share capital is changed from USD$32,000,000.00 divided into 11,200,000,000 granted Class A Ordinary shares with a nominal or par value of USD$0.0025 and 1,600,000,000 Class B Ordinary shares with a nominal or par value of USD$0.0025 each, to USD$32,000,000.00 divided into 112,000,000 Class A Ordinary shares with a nominal or par value of USD$0.25 each and 16,000,000 Class B Ordinary shares with a nominal or par value of USD$0.25 each. The Company's total issued and outstanding Class A ordinary shares will be changed from 158,079,166 Class A ordinary shares with a par value of US$0.0025 per share to approximately 1,580,792 Class A ordinary shares with a par value of US$0.25 per share. The Company's total issued and outstanding Class B ordinary shares will be changed from 480 Class B ordinary shares with a par value of US$0.0025 per share to 5 Class B ordinary shares with a par value of US$0.25 per share.

About Zeta Network Group (Nasdaq: ZNB)

Zeta Network Group (Nasdaq: ZNB) is a U.S.-listed digital infrastructure and financial technology company pioneering the convergence of traditional finance and the digital asset economy. The Company is developing a Bitcoin-centric institutional finance platform that integrates digital asset treasury management, Bitcoin liquidity aggregation, and sustainable Bitcoin mining operations, all within a regulated Nasdaq framework. 

Led by a global team of finance and technology experts, Zeta is redefining institutional digital finance by merging the governance and transparency of a public company with the innovation and scalability of blockchain to create a trusted bridge between capital markets and decentralized finance.

For more information, visit ir.thezetanetwork.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include, among other things, statements regarding anticipated financial performance, strategy, and the potential impact of the transaction described herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Zeta Network Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

SOURCE Zeta Network Group

, /PRNewswire/ -- SOLAI Limited (NYSE: SLAI) (previously traded under "BTCM") ("SOLAI" or the "Company"), a technology-driven personal AI and digital infrastructure provider, today announced it is strategically expanding into personal AI infrastructure. As part of the ongoing optimization of existing operations, the Company unveiled its long-term roadmap for personal AI infrastructure that leverages its established infrastructure capabilities to drive the next phase of AI adoption.

As AI evolves from application-level tools into foundational infrastructure, the industry is rapidly entering the next phase of adoption defined by autonomous AI agents. Because these systems are now capable of reasoning, planning, and executing complex workflows independently, privacy, security, and control are increasingly becoming greater priorities for individuals. To meet these critical demands, SOLAI believes the next major wave of AI adoption will shift intelligence directly to the edge. To drive this transition and enable individuals to operate private, reliable, and independent AI nodes, the Company detailed the architecture of its personal AI infrastructure ecosystem, built upon a fully integrated, four-layer technology stack:

Personal AI Node Device (AI Hardware): Acting as the physical foundation of the ecosystem, this layer offers a dedicated, always-on personal AI node device and is SOLAI's primary differentiator. It features localized storage and robust hardware-level security , enabling secure bridging between local workflows and cloud-based models. On-Device Agent Runtime (System OS): Serving as the proprietary on-device operating system for the personal AI node device, this layer provides a highly stable system for autonomous AI agent execution. It seamlessly integrates model orchestration, an extensible plugin architecture, permission controls, process reliability (auto-recovery/rollback), and update mechanisms, delivering a fully private AI experience with a frictionless setup that requires no technical expertise. Intelligence & Routing (API Management): Functioning as the monetizable traffic and control plane, this layer delivers unified multi-model access through centralized API management. It features intelligent routing, policy control, usage metering, and streamlined billing, securely connecting local devices to several Large Language Models (LLMs) while strictly enforcing data privacy and cost-efficiency. High-Density Compute (AIDC Infrastructure): Designed to expand long-term computing capacity through dedicated AI infrastructure, this layer builds upon SOLAI's extensive experience managing large-scale digital asset mining facilities and data centers. The Company intends to leverage these proven capabilities and deploy them toward high-density AI computing, supporting scalable inference clusters and model deployment as ecosystem demand accelerates. With this roadmap established, SOLAI has begun development of its hardware, operating system, and routing layers, architected seamlessly to ensure a fully integrated experience from inception. The Company has already produced working prototypes of its personal AI node device, which are currently undergoing rigorous system integration testing with the operating system. The software has reached the internal alpha stage, with core capabilities including model orchestration, intelligent routing, and a local knowledge base already operational within the prototype setting. Powered by SOLAI's proprietary operating system and engineered for seamless consumer accessibility, the device will offer native support for the OpenClaw ecosystem straight out of the box. Crucially, the underlying open system architecture ensures long-term adaptability, supporting future software upgrades, optional switching to alternative compatible systems, and eventual multi-system interoperability.

Mr. Bo Yu, Chairman of the Board of SOLAI, commented: "As AI evolves from a cloud-based tool into persistent, autonomous agents, the need for private computing has never been clearer. We believe this marks the start of the next phase of AI adoption, where AI effectively becomes an everyday device — much like laptops, smartphones, and tablets today. This strategic expansion into personal AI infrastructure is a natural progression of SOLAI's long-term vision and leverages our extensive experience in large-scale hardware deployment, data center operations, and high-performance network infrastructure. This roadmap lays the foundation for our personal AI infrastructure ecosystem buildout which we will continue to expand upon. We look forward to sharing our continued progress as we drive the next phase of AI adoption."

About SOLAI Limited

SOLAI Limited (previously known as "BIT Mining Limited") (NYSE: SLAI) (previously traded under "BTCM"), is a technology-driven personal AI and digital infrastructure provider. Building upon its historical legacy in digital asset mining and blockchain network operations, the Company is leveraging extensive experience in large-scale hardware deployment, data center operations, and high-performance computing to build the foundational infrastructure for personal and digital assets globally.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "going forward," "outlook" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Important factors that could cause SOLAI's actual results to differ materially from those indicated in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For further information:
SOLAI Limited
[email protected]
ir.solai.com 
www.solai.com 

Christensen Advisory
Jason Ng
Tel: +852-2117-0861
Email: [email protected] 

SOURCE SOLAI Limited

Cranbrook, British Columbia--(Newsfile Corp. - March 9, 2026) - DLP Resources Inc. (TSXV: DLP) (OTCQB: DLPRF) ("DLP" or the "Company") announces receipt of geochemical results for three (3) of nine (9) trenches in the exotic copper zone and geochemical analysis of gold (Au) and silver (Ag) and a suite of 49 elements in 94 pulps from rock samples taken previously from the Esperanza project immediately south of the Chapi Mine in Southern Peru (Figure 1 and see DLP Resources Inc., news releases dated March 13, 2024 and April 25, 2024).

Results from three of the nine trenches on the exotic copper oxide zone which extends over approximately 300m x 700m have returned copper mineralized intervals of between 48 to 82m with average copper values ranging from 0.29 % Cu to 2.29 % Cu (see Tables 1 to 3 and Figures 2 and 3). Additional analysis of silver (Ag) and gold (Au) plus copper (Cu), Molybdenum (Mo) arsenic (As), antimony (Sb), lead (Pb), bismuth (Bi), barium (Ba) and zinc (Zn) in the re-analysis of pulps of rock samples taken in the initial reconnaissance sampling have returned consistent association of As-Sb-Pb-Bi ± Ba, with anomalous Mo and low Zn, characteristic of proximal phyllic alteration developed above or laterally to a potential mineralized core. This is within mapped intrusive stocks and polymictic breccias within the overlying volcanics (Figures 4 to 14).

The additional geochemical analysis of Au and Ag and the re-interpretation of all geochemical data have confirmed geochemical anomalies over the previously reported magnetic high surrounded by magnetic lows co-incident with mapped porphyry related alteration, high resolution spectral alteration mineral mapping and anomalous copper and molybdenum anomalies (see Figure 14) and DLP Resources Inc., news releases dated January 05, 2026).

Highlights

Trench T1_026 was 54m long and cut through the mineralized zone on an azimuth of 055 degrees and an inclination of -15 degrees (Table 1). The 54m interval returned 1.53% Copper (see Tables 1 & 2).

Trench T2_026 was 48m long and cut through the mineralized zone on an azimuth of 13 degrees and an inclination of -25 degrees. The 48m trench returned an interval of 38m of 0.34 % copper from 10m to 48m (see Tables 3 & 4).

Trench T3_026 was 82m long and cut through the mineralized zone on an azimuth of 10 degrees and an inclination of -25 degrees. The 82m interval returned 0.62 % copper (see Tables 5 & 6).

Rock geochemistry shows a consistent association of As-Sb-Pb-Bi ± Ba, with anomalous Mo and low Zn, characteristic of proximal phyllic alteration developed above or laterally to a mineralized core.

The presence of disseminated tourmaline and the Bi-Mo association supports the interpretation of high-temperature fluids proximal to the intrusive source, with effective vectoring potential toward the center of the porphyry system.

Anomalous Au values concentrated along structures, with generally low Ag, but locally up to 82g/t Ag (~2oz) within a discrete structure, indicate late-stage hydrothermal pulses focused along faults, consistent with a potential telescoped porphyry system and without evidence of extensive epithermal development.

Low surface Cu values over the central RTP - high magnetic anomaly suggests that the Cu-Mo core is not exposed, with a higher probability of occurrence along the flanks of the RTP magnetic high or at greater depth, particularly in zones where As-Sb decrease and Cu-Mo increase (Figure 14).

The elongated reduced to pole (RTP) magnetic high (~3 × 2 km) defines a potential magnetite-bearing intrusive corridor with strong structural control, consistent with a large-scale porphyry system.

Mr. Gendall, President and CEO commented: "Trenching across the exotic copper zone with current mapped exposures of approximately 700m x 300m has returned encouraging intervals of up 82m with very encouraging copper grades of up to 2% copper. These trench results coupled with an elongated magnetic high, proximal phyllic alteration, a well defined As-Sb-Bi-Ba geochemical anomaly over a moderate Mo enrichment, and structurally controlled anomalous Au and Ag defines a well-developed Cu-Mo-Au porphyry system with strong discovery potential through exploration targeting and drilling of these anomalies to depth, along structural flanks and areas of exotic copper showings.

I would also like to welcome Joe Phillips to the DLP Board. Joe brings a wealth of experience to DLP as a senior mining executive and director in North and South America, and we look forward to Joe's insights and guidance as we progress two important copper-molybdenum projects in Peru."

Trench and Rock Chip Sampling

Results from three of the nine trenches on the exotic copper oxide zone which extends over approximately 300m x 700m are reported below (see Tables 1,2,3, 4, 5 & 6 and Figures 2 to 14):

Table 1: Trench T1-026 Location

TrenchEastingNorthingElevationLengthAzimuthInclinationIDmmmmDegreesDegreesT1-02624468681363061860.55455-15Table 2: Trench T1-026 Summary Results for Copper

TrenchFromToIntervalDescriptionCu (total)IDmmm
%T1-02605454Mineralized agglomerate1.53Includes62014Mineralized agglomerate1.88Includes425210Mineralized agglomerate2.29Table 3: Trench T2-026 Location

TrenchEastingNorthingElevationLengthAzimuthInclinationIDmmmmDegreesDegreesT2-026244606813624218694813-25Table 4: Trench T2-026 Summary Results for Copper

TrenchFromToIntervalDescriptionCu (total)IDmmm
%T2-02604848Mineralized agglomerate0.29Includes104838Mineralized agglomerate0.34Table 5: Trench T3-026 Location

TrenchEastingNorthingElevationLengthAzimuthInclinationIDmmmmDegreesDegreesT3-02624449981362541884.58210-25Table 6: Trench T2-026 Summary Results for Copper

TrenchFromToIntervalDescriptionCu (total)IDmmm
%T3-02608282Mineralized agglomerate0.62Includes548228Mineralized agglomerate1.33Table 7. Summary of Rock Chip Results for the Esperanza Project with gold (Au), copper (Cu), zinc (Zn), silver (Ag) and molybdenum (Mo) highlighted.

Sample NoEastingNorthingElevationAuCuZnAgMoSample areaDescription

mmppbppmppmppmppmmRock Chip Samples 2x2m Sampling Area 00115224429381366351965<5151.8360.111.372 x 2Diorite with quartz vlts & Mn, intense fractures with neotacite001153244380813681919536422218270.141.92 x2Quartz Diorite, FeOx + Malachite + Mn + Tm?001154244459813684819536041326630.191.042 x2Quartz Diorite, Intense fractures, Malachite + CuOx + Mn + Tm001155244517813688319511114016510.170.972 x2Quartz Diorite, QS alteration, FeOx + Malachite 00115624433481366611943<542.5640.161.242 x2Quartz Diorite, Argillic alteration, FeOx vlts00115724436781367021940827.7540.171.32 x2Quartz Diorite, FeOx vlts + calcite00115824440081367391930830990.136.382 x2Quartz Diorite, Arg alteration, Qtz vlts00115924445181367081940721.3590.217.292 x2Quartz Diorite, Arg alteration, Qtz Veinlets + FeOx00116024453081365361929<524.6660.287.52 x2Aplite Dyke, FeOx + Neotocite00116124471981363241959<53847033870.222.122 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn00116224471481363291959<52870022000.182.352 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn0011632447238136311195553296017510.182.442 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn00116424467481363131853<53821017160.191.852 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn0011652443828136816195463068014940.181.822 x2Quartz Diorite, FeOx, CuOx, Malachite + Mn + Tm?0011662443848136818195419193114600.131.142 x2Quartz Diorite, FeOx, CuOx, Malachite + Mn + Tm?00116724438681368201953501111019050.131.82 x2Quartz Diorite, FeOx, CuOx, Malachite + Mn + Tm?00116824438881368221953126573370.120.662 x2Quartz Diorite, FeOx, CuOx, Malachite + Mn + Tm?0011692443908136824195315368529330.151.32 x2Quartz Diorite, FeOx, CuOx, Malachite + Mn + Tm?00117124440981367391930134493028740.272.112 x2Quartz Diorite, Arg Alteration, Qtz Vlts, FeOx, + Vlts Calc0011722447198136324193254558018290.172.322 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn001173244714813632918538981724930.491.842 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn00117424472381363111853171461011390.21.672 x2Polymictic Bx, Qtz + Tm + Ox Cu + Mn00117524810981321641675<5182800.271.392 x2Qtz Tm Breccia with Cp, CuOx, FerriMo, Int Frac00117624928881333801930<540.8320.080.842 x2Diorite? With Volc frag., 00117724428381367511913678.8690.111.292 x2Qtz Monzonite with Bi + Chl + FeOx vlts, Neo + Tm00117824431981367901917740.1690.1612 x2Qtz Monzonite, Arg Alteration, FeOx vlts, Neo + Tm00117924421681367771922828.2740.261.182 x2Qtz Monzonite,Qtz vlts-calcite-ep-mag001180244169813674919316191250.680.622 x2Qtz Monzonite +Tm-Qtz-bi, Neo00118124417081367511942<531.3660.271.492 x2And Dyke, Intense Frac.,Vlts of FeOx00118224400981367431955<537.2670.60.972 x2Qtz Monzonite with Arg alt, Intense Frac-vlts-FeOx00118324405681368051987<523.2620.140.822 x2Qtz Monzonite with Vlts of Mn, Calcite, Tm-Mag zones001184249618813577119571026710.220.752 x2Qtz Dirorite, Arg Alt, Vlts of FeOx, green sericite00118524964081357551957671.61380.590.882 x2Qtz-Tm dyke?00118624319581356441940<529.8830.191.152 x2Qtz Diorite with Chl-py-ep + Mn00118724291781354271935636.8410.233.022 x2Diorite with FeOx + Discontinuous vlts001188241824813445619176653.5650.2114.762 x2Breccia, FeOx, Lim boxworks001189241913813461519222148.6220.327.612 x2Polymictic Bx, FeOx in fractures001191242573813544719301255.9700.2210.732 x2Quartz vein, Strong Fracturing with FeOx + Mn00119224325881346311926894.71030.257.62 x2Andesite fragment, FeOX, Intense Fracturing00119324328281346461929526.8300.112.752 x2Quartz Diorite, QS Alteration, Very Fractured00119424312581347451929734440.133.332 x2Quartz Diorite, FeOx, Turgite,00119524334181347971925<528.3740.443.632 x2Quartz Diorite, FeOx, Turgite, Intense Fractures00119624347281344711924621.2390.2514.422 x2Quartz Diorite, Quartz Vlts, FeOx boxworks, Intense Frac.00119724326681341641917732.4900.254.112 x2Diorite with Qtz Vlts, Leached - FeOx + Qtz Tm vlts001199246227813000319212830.2411.586.162 x2Diorite with Vlts of Qyz-py-mn = Sulphates + Int Frac.00120024347881343341718694630.314.142 x2Diorite with fragments of SS + Vlts of Qtz-hm,Mn,NeoNotes: Bx-Breccia, Qtz-Quartz, Tm-Tourmaline, Vlts-veinlets, FeOx-Iron Oxides, FeMo-ferrimolybdenite, Mt-magnetite, SS-sandstone, Py-Pyrite, Ep-Epidote, Chl-Chlorite, Arg-Argillic, QSP-Quartz-sericite-pyrite, Ser-Sericite, Sil-Silicified, SS-sandstone, Py-Pyrite, Ep-Epidote, Chl-Chlorite, Arg-Argillic, QSP-Quartz-sericite-pyrite, Ser-Sericite, Sil-Silicified,Sample NoEastingNorthingElevationAuCuZnAgMoSample areaDescription

mmppbppmppmppmppmmRock Chip Samples 2x2m Sampling Area00120124318581345761711<532.7340.1715.52 x2Qtz-Tourmaline breccia00120224308581345751721638.5630.0721.622 x2Intensely fractured diorite with FeOx boxworks001204243094813458517101164.2840.1337.962 x2Diorite with SS clasts and Fe-oxides + Tourmaline00120524310281345841721<536.9570.0819.12 x2Sandstone with Fe-oxides + Quartz-sericite001206243107813457017121452.4170.2334.582 x2Diorite, Arg Alt, with Vlts of FeOx = Int Frac0012072431518134507171427211.61010.139.042 x2Diorite + Veining with FeOx + Mn + Neo + Tm0012092431418134293171637282.21260.1112.062 x2Diorite, Arg with SS and Qtz vlts and FeOx boxworks +Tm001210243330813445417298328.7440.1139.912 x2Diorite, Arg with SS and Qtz vlts and FeOx boxworks +Tm00121124284481346761728436231.31400.11362 x2Diorite, Arg altered, qtz-FeOx + Tm + fine alunite? in matrix.00121224280281347571721727.9510.256.672 x2Diorite Sil, Qtz vlts, Mn-Tm, intense angular fractures.0012142427548134817172911106.4240.1119.452 x2Diorite, Arg Alteration, Vlts of Qz, FeOx, Mn +Tm00121524271881348461728873.1330.0821.72 x2Polymictic Bx frag of SS with FeOx veins + Mn001216242911813483317162083.3220.094.742 x2Polymictic Bx, fragments of SS, vlts of FeOx, Mn + Neo00121724286581349181718794.1220.067.762 x2Diorite QSP with Qtz vlts and FeOx-Mn00121924287281349711711<53.660.040.172 x2Diorite, QS alt, vlts of Qtz + FeOx +Mn + Neo00122024275681350471674641690.315.422 x2Diorite, QS alt, vlts of Qtz + FeOx +Mn + Neo = Int Fac00122124267381350041691<523.4330.175.92 x2Diorite, Arg alt, vlts of Qtz + FeOx +Mn + Tm001222242872813497116851149.11070.271.642 x2Diorite, Qtz-Tm, Int Frac, vlts of FeOx-Mn + Neo001224242756813504716804716.8140.313.532 x2Polymictic bX with Sil fragments with BxWks + vlts of FeOx-Mn, Int Frac001225242673813500416791119.8190.081.582 x2Diorite, arg alt, Vlts of FeOx, +Mn + Tm00122624450481363211886<51905010990.191.972x2Polymictic Bx, pseudostratification + malachite and Mn0012272446828136164185281778023950.366.483 x5Polymictic Bx, pseudostratified with presence of malachite00122924481781361811852163941013890.4916.942 x2Polymictic Bx?, with malachite and Mn in matrix00123024460981362241887<543633500.236.063 x3Polymictic Bx?, with malachite and Mn in matrix0012312445578136198158951441011190.133.335 x5Polymictic Bx?, with malachite and Mn in matrix001232244500813615218841465034600.164.335 x 5Subhorizontal polymictic Bx with malachite and Mn in matrix00123424449481361081876<539865510.145.135 x 3Polymictic Bx with malachite and Mn in subhorizontal horizons00123524451881360331878940785100.195.535 x 5Polymictic Bx with malachite and Mn in subhorizontal horizons001236244564813608018539761212470.269.113 x 10Polymictic Bx with malachite and Mn in subhorizontal horizons0012372445878135958185627158407640.347.55 x 5Polymictic Bx with malachite, atacamite and Mn00123924451381358801863923863920.235.46 x 3Polymictic Bx with malachite in a subhorizontal horizon00124024451081357921861<576014200.194.665 x 5Polymictic Bx with malachite in a subhorizontal horizon00124124456881356791852<536715150.26.75 x 5Polymictic Bx with malachite in a subhorizontal horizon00124224401081353531789<5111720910.213.865 x 3Polymictic Bx with malachite in a subhorizontal horizon0012442440658135443179222307514530.25.325 x 3Polymictic Bx with malachite in a subhorizontal horizon00124524271881344031674585.6340.115.155 x 2Diorite, Arg., with Mn in irregular veins0012462429858134540169111150.22400.0850.85 x 5Diorite, Arg., with Mn in irregular veins00124724283081343641667823.3610.0923.182 x 2Diorite, Qtz, Tm, FeOx in boxworks + intense fracturing + veins00124924267481342001645751.7490.26.282 x 2Quartzite/SS with FeOx in veinlets/fractures and presence of Tm00125024264081341581637733.8120.2618.185 x 3Quartzite/SS with FeOx in veinlets/fractures and presence of Ser001751242562813409316286105.6440.3325.795 x 2Bx of quartzite/SS with FeOx boxworks + FeOx in fractures001752242082813462716261435.6810.1713.763 x 3Diorite, Arg, FeOx + quartzite/SS with FeOx boxworks00175424225481344341645370161.5728267.155 x 2Vein?, QSP, malachite and OxFe in fractures and boxworks00175524229181342491634729.770.2514.763 x 2Bx, QSP +FeOx boxworks +quartz00175624227681342441643622.7250.135.623 x 2Bx, QSP, presence of FeOx boxworks + quartz00175724224881342201651816.91360.1411.673 x 3Bx, subangular fragments, Qtz-Tm?0017592423518134070160710031.3280.6611.463 x 3Diorite, QSP, FeMo in fractures, FeOx +intense fracturing001760242265813416816442547.51140.5415.335 x 3Bx, quartz veins with FeOx, Mn and Tm in fracturesNotes: Bx-Breccia, Qtz-Quartz, Tm-Tourmaline, Vlts-veinlets, FeOx-Iron Oxides, FeMo-ferrimolybdenite, Mt-magnetite, SS-sandstone, Py-Pyrite, Ep-Epidote, Chl-Chlorite, Arg-Argillic, QSP-Quartz-sericite-pyrite, Ser-Sericite, Sil-Silicified, SS-sandstone, Py-Pyrite, Ep-Epidote, Chl-Chlorite, Arg-Argillic, QSP-Quartz-sericite-pyrite, Ser-Sericite, Sil-Silicified,Board Appointment and Issuing of Options

Mr. Joe Phillips, who served as a Technical Advisor to DLP from December 2025 is appointed to the Board. Mr. Phillips has a wealth of experience as a senior mining executive and director in North and South America. His experience ranges from startup and development to operational roles at a senior level. He has acted as technical adviser on various operations, most recently the World Copper project in Arizona, and has been COO at a number of operations including Minera Tres Valles, Chile, and Laguna Gold. He has been in senior management roles with Coeur Mining, Silver Standard and Pan American Silver.

The Company has granted 200,000 incentive stock options to Mr. Phillips with an exercise price of $0.36 per share for a five-year period, from the date of grant, in accordance with the terms of DLP Resources Inc. stock option plan. Further, the Company has granted an at arm's length consultant 100,000 incentive stock options with an exercise price of $0.36 per share for a five-year period, from the date of grant, in accordance with the terms of DLP Resources Inc. stock option plan.

Quality Control and Quality Assurance

DLP Resources Peru S.A.C, a subsidiary of DLP Resources Inc., supervises sampling and carries out surface sampling and mapping of outcrop at the Esperanza project. Rock chip-Panel sampling was done within a maximum area of 2m x 1m and descriptions were carried out by a geologist. Samples are bagged and sealed on site before transportation to the SGS Peru S.A.C. sample preparation facility in Arequipa by Company vehicles and staff. Rocks are crushed Drying at 100°C, primary and secondary crushing to -10 mesh (up to 6K) Division and pulverizing of 250g (95% to 140 mesh) with 70% passing <2mm. Sample is split with riffle splitter and 250g pulverized to 85% less than 75um. Prepared samples are sent to Lima by SGS Peru S.A.C. for analysis. SGS Peru S.A.C. is an independent laboratory. Samples are analyzed for 50 elements using a four-acid digestion and Atomic absorption spectroscopy finish. Overlimit samples for copper and silver were re-analysed by four-acid digestion and atomic absorption spectrometry finish). For gold determination, fire assay of a 30 g charge is followed by an atomic absorption spectroscopy (AAS) determination. In addition, sequential copper analyses are done and reports, soluble copper using sulphuric acid leach, soluble copper in cyanide leach, residual copper and total copper. SGS meets all requirements of International Standards with ISO/IEC 17025 accredited testing laboratories.

DLP Resources independently monitors quality control and quality assurance ("QA/QC") through a program that includes the insertion of certified reference materials.

Esperanza Project

The Esperanza Cu-Mo Project is an early-stage exploration project in Southern Peru consisting of 13,900 Ha of claims which are 100% owned by DLP. Esperanza is located ~35 km SW of the Cerro Verde Mine in Arequipa and immediately south of the Chapi Copper Mine.

Copper-molybdenum mineralization was initially observed in an early reconnaissance program undertaken in 2022. Subsequently we have completed a satellite alteration mapping program over the project and identified alteration consistent with porphyry copper-molybdenum systems. Follow-up of alteration and subsequent sampling and mapping commenced in early 2024.

Figure 1: Esperanza Project Location

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_001full.jpg

Figure 2: Esperanza Trench Locations

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_002full.jpg

Figure 3. Summary of rock chip-panel sample results from the three trenches for the Esperanza Porphyry Project.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_003full.jpg

Figure 4: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous copper (Cu) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_004full.jpg

Figure 5: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous molybdenum (Mo) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_005full.jpg

Figure 6: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous gold (Au) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_006full.jpg

Figure 7: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous silver (Ag) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_007full.jpg

Figure 8: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous arsenic (As) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_008full.jpg

Figure 9: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous antimony (Sb)in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_009full.jpg

Figure 10: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous bismuth (Bi) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_010full.jpg

Figure 11: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous barium (Ba) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_011full.jpg

Figure 12: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous lead (Pb) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_012full.jpg

Figure 13: Esperanza Project - Reduced to pole magnetic map and geology map with anomalous zinc (Zn) in rock samples.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_013full.jpg

Figure 14: Esperanza Project - Rock chip anomalies of arsenic (As), gold (Au), barium (Ba), antimony (Sb), copper (Cu), molybdenum and alteration anomaly of limonite and sericite on magnetic signature - reduced to pole (RTP) data.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6456/287687_5948ca81b4e1dab1_014full.jpg

Qualified Person

Mr. Gendall, CEO & President of the company is the qualified person as defined by National Instrument 43-101. Mr. Gendall has reviewed and approved the technical contents of this news release

About DLP Resources Inc.

DLP Resources Inc. is a mineral exploration company operating in Southeastern British Columbia and Peru, exploring for Base Metals and Cobalt. DLP is listed on the TSX-V, trading symbol DLP and on the OTCQB, trading symbol DLPRF. Please refer to our web site www.dlpresourcesinc.com for additional information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to further sampling, mapping and advancement of the Esperanza Project in Peru.

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things rock chip results expected from the Esperanza Project in Peru.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287687

Source: DLP Resources Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell lines IDE892 is being evaluated as a monotherapy agent in MTAP-deleted solid tumors, including NSCLC and PDAC, and targeting combination FPI with IDE397 (MAT2A) in mid-2026 Targeting nomination of a first-in-class CDKN2A development candidate in H2 2026 and IND in H1 2027; prevalence of CDKN2A-deficiency has been reported at over 80% in PDAC IDEAYA will deprioritize combination activities with Trodelvy as part of a strategic prioritization of its proprietary MTAP-deleted and CDKN2A pipeline SOUTH SAN FRANCISCO, Calif., March 9, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer.

March 09, 2026 06:02 ET  | Source: Shell plc

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU AND UK MARKET ABUSE REGIMES

March 9, 2025

1. Details of the person discharging managerial responsibilities/person closely associatedFirst Name(s)RachelLast Name(s)Solway2. Reason for the notificationPosition/statusChief Human Resources and Corporate OfficerInitial notification/amendmentsInitial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitorFull name of the entityShell plcLegal Entity Identifier code21380068P1DRHMJ8KU704. Details of the transaction(s) section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date, (iv) each place where transactions have been conductedDescription of the financial instrumentOrdinary shares of €0.07 eachIdentification CodeGB00BP6MXD84Nature of the transactionDisposal of ordinary sharesCurrencyGBPPrice £31.00Volume 9,000Total £279,026.65Aggregated information:Price £31.00Volume 9,000Total £279,026.65Date of transactionMarch 5, 2026Place of transactionOutside a trading venue1. Details of the person discharging managerial responsibilities/person closely associatedFirst Name(s)PhilippaLast Name(s)Bounds2. Reason for the notificationPosition/statusChief Legal OfficerInitial notification/amendmentsInitial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitorFull name of the entityShell plcLegal Entity Identifier code21380068P1DRHMJ8KU704. Details of the transaction(s) section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date, (iv) each place where transactions have been conductedDescription of the financial instrumentOrdinary shares of €0.07 eachIdentification CodeGB00BP6MXD84Nature of the transactionDisposal of ordinary sharesCurrencyGBPPrice £31.07Volume 6,000Total £186,420Aggregated information:Price £31.07Volume 6,000Total £186,420Date of transactionMarch 6, 2026Place of transactionLondon Stock Exchange Julie Keefe
Deputy Company Secretary

ENQUIRIES

Shell Media Relations
International, UK, European Press: +44 20 7934 5550

LONDON & DENVER & JOHANNESBURG--(BUSINESS WIRE)--AngloGold Ashanti plc (the “Company”) (NYSE: AU; JSE: ANG) announces that Executive Directors, Alberto Calderon and Gillian Doran, have dealt in securities of the Company. Name of Executive Director Alberto Calderon Name of Company AngloGold Ashanti plc Date of transaction 6 March 2026 Nature of transaction Off-market receipt of vested shares under the 2023 Deferred Share Plan (DSP) Class of security Ordinary shares Number of securities 80,296 Pr.

Bringing AI-powered radio promotion directly to artists and music industry professionals

Building on the 5,000 music submissions by artists during the MVP launch

BOULDER, CO, March 9, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Auddia Inc. (NASDAQ: AUUD) (NASDAQ: AUUDW) (“Auddia” or the “Company”), an AI-first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced its official brand activation for Discovr Radio at the 2026 South by Southwest® (SXSW®) Conference and Festivals.

As part of its SXSW presence, Auddia will host six Discovr Radio Demo Listening Events, interactive sessions where artist attendees have the opportunity to play demos of their music for industry professionals—producers, A&R representatives, artists, and publishers—sparking real-time feedback and meaningful industry connections. Each event has a capacity of 150 to 200 people and reservations are open to any SXSW attendee as well as any of the 1,000+ showcasing artists.

“These events are a particularly good fit for Discovr Radio, which exists to help artists promote their music and also get meaningful metrics and feedback from real listeners. We are thrilled to partner with SXSW for these activations.”

Theo Romeo, Chief Marketing Officer of Auddia In addition to the demo sessions, Auddia will maintain an active presence at the SXSW Artists Lounge, where the Company will host a dedicated booth to meet directly with independent artists, managers, and label representatives. Throughout the week, Auddia’s street team will be networking across official showcases, panels, and industry gatherings to introduce Discovr Radio to emerging talent and music industry stakeholders.

The activation comes on the heels of Discovr Radio’s successful MVP rollout within the faidr app, where early campaigns demonstrated strong listener engagement and downstream interaction beyond passive stream listening. By showcasing the technology in a live festival environment, Auddia aims to accelerate artist onboarding and expand awareness of its music promotion engine beyond the early success of initial marketing efforts that resulted in over 5,000 music submissions between the January launch and March 5, 2026.

“Our mission is to align listeners, artists, and the radio ecosystem through intelligent, data-driven discovery. SXSW provides the ideal stage to connect directly with the creative community and demonstrate how Discovr Radio delivers both guaranteed exposure and transparent performance insights.”

Jeff Thramann, CEO of Auddia Artists and industry professionals attending SXSW 2026 are encouraged to attend one of the scheduled Demo Listening Events or visit the Discovr Radio booth in the Artists Lounge to learn more about participating in upcoming campaigns. SXSW attendees can see the full list of all Discovr Radio sponsored events at https://schedule.sxsw.com/search/event/?q=demo+listening&models=event

For more information about Discovr Radio, visit www.discovrradio.com.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

Ad-free listening on any AM/FM music station Content skipping across any AM/FM music station One-touch skipping of entire podcast ad breaks Integrated artist discovery experiences For more information, visit www.auddia.com

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction;

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2024, which was originally filed with the SEC on March 5, 2025,subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time.  Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia’s Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia with investors and the public using its website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 5, 2025. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:

Kirin Smith, President
PCG Advisory, Inc.
[email protected]
www.pcgadvisory.com

Source: Auddia Inc.

The latest news and updates relating to $AUUD are available in the company’s newsroom at: https://tinyurl.com/auudnewsroom

PMW on Newsramp: https://newsramp.com/newswire/prism

Add us on Google as a Preferred Source to see more News in your Search Results

Dag J. Opedal

Good morning. My name is Dag Opedal, and I'm the Deputy Chairman of the Board of Directors of Elkem ASA. Before we start the official general meeting, I first wish to give you some practical information.

Our secretarial function today is managed by DNB registrar department. They will be in charge of registration and counting of shares represented in the meeting and in due course, the counting of the votes cast at the meeting. As you are aware, this meeting is conducted as a virtual meeting.

I assume that most shareholders present are well acquainted with the digital general meetings conducted by use of the Lumi platform. And for them, which this solution is new, you will find information under the home button.

Agenda item #1. I welcome you all to this extraordinary general meeting of Elkem ASA. Together with me are our CFO, Morten Viga; Senior Vice President for Business Development, Morten Magnus Voll; and Head of Investor Relations, Odd-Geir Lyngstad. Present is also Hans Cappelen Arnesen from the law firm, Thommessen.

I will now refer to the list of represented shares here today. 19,751,630 shares are represented by proxy. 131,375,379 shares are represented by advanced votes. 338,338,536 shares are represented by instructions to the Chairman or myself. For shareholders participating online and representing in aggregate 159,006 shares. In aggregate, this is 489,624,551 shares represented, which constitutes 77.2% of the share capital.

We now move on to Item #2 on the agenda, where the Board of Directors has proposed that Hans Cappelen Arnesen, partner with Thommessen, is elected to chair the meeting and Morten Viga, our CFO, is elected to co-sign the minutes together with the Chair

, /PRNewswire/ -- In response to recent geopolitical developments in the Middle East and fluctuations in global energy markets, Benjamin Zhai, Chief Executive Officer of Nasdaq-listed Robo.ai Inc. (NASDAQ: AIIO), a technology company developing a global artificial intelligence machine economy platform, recently sat for an in-depth interview with a financial media outlet. During the discussion, Mr. Zhai addressed the current macro environment, including geopolitical dynamics and global energy price fluctuations. He stated that the UAE's position as a global technology and innovation hub demonstrates counter-cyclical resilience. He noted that Robo.ai is aligning with the UAE's national strategic initiatives, maintaining its local technology investments, and focusing on commercial fundamentals to deliver operational results to the capital markets.

Historical precedent supports this view. During the 2008 global financial crisis, the UAE pursued economic diversification. He cited the 2008 global financial crisis, during which the UAE advanced its economic diversification. During this period, Dubai utilized sovereign capital to complete debt restructuring and shifted its strategic focus to physical infrastructure, including the expansion of the Jebel Ali Free Zone (Jafza) deep-water berths and automated port facilities. Concurrently, Emirates Airline expanded its fleet and route network, establishing Dubai as a major aviation transit hub. These measures promoted the growth of non-oil trade, which currently accounts for over 73% of the UAE's Gross Domestic Product, establishing the region as a financial and logistics center. Furthermore, during recent global supply chain realignments, the UAE facilitated the influx of technology professionals and multinational corporate headquarters through its governance and open economic policies. Mr. Zhai stated that corporate development must align with economic cycles, and Robo.ai relies on the UAE's strategic stability to pace its commercial execution and internal growth.

Describing the UAE's technology landscape, Zhai outlined a coordinated national ecosystem with clear divisions of labor. "The UAE has far-sighted policy direction at the top, with sovereign funds responsible for integrating foundational computing power, technology, and capital. Robo.ai's role within this framework is to deliver the application layer that brings this ecosystem to market."

He identified three core components of this ecosystem:

Policy Framework: Under the National AI Strategy 2031, the UAE aims for artificial intelligence to contribute approximately 14 percent of GDP (USD 96 billion) by 2031. The country is advancing large-scale AI computing infrastructure projects to support foundational models for general artificial intelligence. The Dubai Autonomous Transportation Strategy, which targets 25 percent of all journeys to be autonomous by 2030, provides a regulatory environment for commercial deployment of smart mobility technologies.

Capital Infrastructure: Strategic capital has built the foundational infrastructure. Three sovereign wealth funds, ADIA, Mubadala and L'IMAD Holding, together with the AI group G42, form a capital-technology partnership deploying significant resources into global technology sectors. He noted Mubadala and G42 recently formed MGX, a technology fund targeting over $100 billion in assets under management across semiconductors, core models, and AI infrastructure. L'IMAD Holding, having integrated ADQ's asset portfolio, is restructuring sectors such as intelligent transportation, smart cities, and modern logistics, providing physical application scenarios for next-generation autonomous driving and eVTOL technologies. G42 has secured a $1.5 billion strategic investment from Microsoft, strengthening the UAE's foundational model environment and supporting algorithmic development for upper-layer applications.

Application Layer: Mr. Zhai stated that while national policies and sovereign capital build the AI computing foundation, Robo.ai commercializes this infrastructure through an intelligent physical transportation network. He noted that computing power and large model parameters require physical carriers to complete the commercial loop and generate investment returns. Robo.ai integrates AI software, intelligent hardware, and smart assets to connect with these policy and capital initiatives. Policy initiatives like the Dubai Autonomous Transportation Strategy provide the operational rights for Robo.ai to deploy algorithms into physical entities such as its RoBUS commercial vehicles and Robotaxis, generating commercial mileage and transport orders. Furthermore, Robo.ai's physical operations produce high-quality physical interaction data that feeds back into the foundational models. Using the recently delivered embodied AI data order from its joint venture with DaBoss.AI as an example, Mr. Zhai explained that Robo.ai generates multimodal, high-precision data through the operation of physical robots, driving the iteration of foundational models and creating an economic cycle of computing monetization, data production, and model refinement.

Robo.ai is advancing its operations through its joint venture with Silicon Valley-based DaBoss.AI, focusing on embodied AI data services. Mr. Zhai explained that the transition from large language models to embodied AI faces a "Sim-to-Real" gap, requiring multimodal interaction data containing real-world physical properties, such as high-precision spatial vision, six-degrees-of-freedom motion trajectories, and force-control tactile feedback. Market research indicates the global AI training data collection and annotation market may exceed $10 billion by 2030, with high-quality physical interaction data representing a rapidly growing segment. The joint venture utilizes tele-operation equipment and multimodal data screening technology to convert human behaviors into digital intelligence. Benefiting from the UAE's data compliance environment and international workforce, Robo.ai provides the operational capacity for this standardized data collection. Following the execution of a data collection services agreement, the joint venture completed its initial commercial delivery of embodied AI data within weeks. Mr. Zhai emphasized that this delivery advances Robo.ai's previously disclosed 30,000-hour embodied AI data backlog, demonstrating the Company's ability to commercialize frontier technologies and market demand.

Mr. Zhai concluded that the UAE provides the policy environment and sovereign capital foundation for technology companies. He stated that Robo.ai has identified its strategic position within this national technology framework and will focus on commercializing frontier technologies through continued high-quality deliveries, acting as the application execution component of the global intelligent machine economy ecosystem.

About Robo.ai Inc.

Robo.ai Inc. (NASDAQ: AIIO) is a technology company dedicated to building a leading global artificial intelligence machine economy platform. Its mission is to integrate "AI Software, Intelligent Hardware, and Smart Assets" to construct a unified AI operating system and an ecosystem empowered by blockchain, pioneering an intelligent future.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those anticipated; for further details, please refer to the Company's filings with the U.S. Securities and Exchange Commission.

SOURCE Robo.ai Inc.

Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF, FRA:5CT) told investors the Yellow Network has now launched the YELLOW token and Yellow Pro trading platform, describing these steps as moving the project into live operations.

As a result, it is now staked in Yellow, which is designed to be a decentralised trading platform and clearing house for digital assets, following its early-stage investment and collaboration with the Yellow team.

“We warmly congratulate the Yellow team on reaching this significant milestone with the launch of their token and trading platform," Coinsilium chief executive Eddy Travia said.

"Bringing a project of this ambition from early concept through years of development to a live network launch is a remarkable achievement and reflects an extraordinary amount of vision, perseverance and technical execution."

The company, in an announcement, noted that the rollout began on Sunday, with the firm's own total allocation amounting to 50 million YELLOW tokens.

Tokens will vest under their respective terms on a linear basis over as much as three years, after an initial cliff period of between two and six months, Coinsilium noted.

It also said it is in discussions with the Yellow team over possible further collaboration, including backing projects built on the Yellow SDK and using its venture-building and advisory capabilities to support the network’s expansion.

The board flagged that early trading in newly launched digital assets often comes with volatile price discovery and shifting liquidity, and said short-term market moves may not reflect longer-term adoption as exchange integrations and participation build.

Travia highlighted: "As longstanding backers, we have had the privilege of seeing the Yellow project steadily progress to this moment... the team has pursued a bold vision to build infrastructure designed to fundamentally reshape how liquidity and connectivity operate across digital asset markets. The launch represents the culmination of many years of work and the beginning of the next chapter as the Yellow ecosystem enters live operation, and we look forward to continuing to collaborate with and support the team.”

In late October, prediction market traders were giving Bitcoin (BTC +0.76%) a 60% chance of hitting a price of $150,000 by the end of March 2026. At the time, Bitcoin was trading near an all-time high of $126,000 and its future looked very bright indeed.

But, my, how times have changed. Bitcoin has since crashed down to the $72,000 price level, and shows no signs of heading higher any time soon. As a result, prediction markets are paying just pennies for "yes" on $150,000 Bitcoin by the end of March. How should you weigh this collapse of prediction market sentiment when considering Bitcoin's trajectory over the next 12 months?

The four-year Bitcoin cycle It's important to keep in mind that Bitcoin historically has followed a four-year cycle of boom and bust. Three good years are typically followed by one very bad year in which Bitcoin loses 57% or more of its value.

Today's Change

(

0.76

%) $

508.55

Current Price

$

67809.00

If history is any guide, then Bitcoin is in line for one of those very bad years in 2026. After all, previous Bitcoin price collapses have occurred in 2014, 2018, and 2022. So it makes sense that Bitcoin could suffer another major price collapse in 2026.

Bitcoin is already down 25% for the year, and there's likely more pain on the way. Some bearish analysts are already talking about $40,000 Bitcoin and even $20,000 Bitcoin. Things could get really nasty, really fast.

If you believe in the four-year Bitcoin cycle, then prediction markets appear to be offering a clear warning to investors: "Stay away." In other words, this is not your typical buy-the-dip opportunity with Bitcoin. Some have already drawn a parallel to the crypto winter of 2022, when Bitcoin fell in price by 64%.

Can you make money betting against Bitcoin? The obvious conclusion here is that you should be buying up those March 2026 event contracts, hoping that Bitcoin continues to trade sideways or down, right?

Image source: Getty Images.

Wrong. From my perspective, there's not much meat on the bone in this trade. On Polymarket, the odds of Bitcoin hitting $150,000 by the end of March are currently just 1%. Right now, a "yes" contract costs $0.016 and a "no" contract costs $0.987.

If you are absolutely convinced that Bitcoin can't hit $150,000 by the end of March, then you could pay $100 for "no" contracts in order to win $101.32. It's almost not even worth it.

I'd almost rather take the opposite side of this trade. I could pay $100 for "yes" contracts and earn $5,252.15 if Bitcoin somehow pulls off some March madness.

Wait for 2028 A better idea, though, might be to wait for 2028. That's when the next Bitcoin halving is scheduled to take place. According to the four-year Bitcoin cycle, that's also when the "boom" phase of the cycle is expected to kick into high gear.

The same thing happened in 2024. After a halving event in April, Bitcoin rallied hard after the election. It eventually reached $100,000 by the end of the year.

I'm not betting against Bitcoin right now. Instead, I'm expecting Bitcoin to follow the same trajectory that it has in previous boom-and-bust cycles. That means a price decline in 2026 could end up rewarding long-term investors. A modest upfront investment in Bitcoin now could pay off big later.

Key Takeaways Table of Contents

Key TakeawaysSTRC Preferred Shares See Record Trading VolumeBitcoin Faces Macroeconomic ChallengesGet 3 Free Stock Ebooks Michael Saylor shared his characteristic weekend message on X, indicating Strategy may be preparing to acquire additional Bitcoin. The company’s most recent acquisition occurred during February’s final week: 3,015 BTC purchased for $204.1 million at approximately $67,700 each. Strategy’s Bitcoin treasury currently comprises 720,737 BTC, with an average acquisition cost of $75,985 per coin. STRC preferred shares recorded unprecedented 2026 trading activity at $260M on March 6. At the time of publication, Bitcoin traded near $67,292, positioning it below Strategy’s average buy-in price. Bitcoin hovered around $67,500 when Michael Saylor posted a cryptic message to X on Sunday: “The Second Century Begins.” Accompanied by Strategy’s characteristic Bitcoin accumulation visualization, the post carries familiar weight for those tracking the company’s investment pattern. The implication is clear: another acquisition appears imminent.

This approach has become Saylor’s trademark strategy in recent months. A weekend social media post emerges, followed typically by Monday regulatory disclosures confirming fresh Bitcoin purchases. The pattern has evolved into one of the crypto market’s more reliable indicators.

Strategy completed its latest Bitcoin acquisition during February’s closing week, securing 3,015 BTC through a $204.1 million transaction at roughly $67,700 per unit. This purchase elevated the company’s aggregate holdings to 720,737 BTC, representing approximately $54.77 billion in total capital deployed.

Strategy Inc, MSTR

According to SaylorTracker analytics, the firm’s average Bitcoin acquisition price stands at $75,985. With current BTC prices hovering around $67,292, Strategy finds itself holding positions below its cost basis.

Strategy’s fundamental net asset value (NAV) has dipped marginally below 1.0, indicating the stock trades at a discount relative to its Bitcoin treasury value. This marks a notable departure from the premium valuation the company maintained throughout much of 2024 and into early 2025.

STRC Preferred Shares See Record Trading Volume Market participants closely monitor STRC preferred stock activity as a leading indicator for potential Strategy Bitcoin purchases. March 6 witnessed STRC trading volume surge to $260 million — establishing a new 2026 benchmark.

Market observers interpret heightened STRC trading as evidence of capital formation preceding Bitcoin acquisitions. The at-the-market offering structure connected to this instrument enables investor demand transformation into deployable capital, a mechanism Strategy has leveraged for previous major purchases.

Anchorage’s recent STRC portfolio addition has amplified institutional focus on the instrument. Confirmation of any new purchase will ultimately arrive through official SEC documentation.

Bitcoin Faces Macroeconomic Challenges Bitcoin’s price trajectory has encountered resistance throughout recent weeks. The cryptocurrency market broadly has grappled with constrained liquidity conditions and macroeconomic uncertainty.

CryptoQuant analyst Darkfost identified persistent inflation and climbing unemployment figures as primary factors pressuring risk-oriented assets. Latest Nonfarm Payrolls figures disappointed expectations, intensifying pressure on markets already navigating ambiguous Federal Reserve policy signals.

Liquidity constraints have tightened across global financial markets. BlackRock’s recent decision to restrict investor redemptions in one fund due to liquidity limitations underscores the severity of current market conditions.

Nevertheless, Strategy has maintained its acquisition strategy. The company finances Bitcoin purchases through debt and equity instruments rather than operational cash generation, enabling continued accumulation independent of near-term price fluctuations.

Saylor has additionally dismissed potential mergers with competing Bitcoin treasury firms. In comments to Cointelegraph, he explained that transaction timelines typically span six to nine months or longer, during which market conditions can shift sufficiently to undermine deal attractiveness.

Strategy maintains its position as the world’s largest corporate Bitcoin holder, with 720,737 BTC secured on its balance sheet.

Oil trading accelerated on Hyperliquid, with two contracts now active. Whales are also taking bolder positions on expectations of oil extending its trend. 

Hyperliquid now offers both Brent and WTI oil trades through HIP-3 and the XYZ exchange. The futures became active in the past week, as oil broke above $90. 

Whales are also making even bolder bets on expectations of oil expansion. The Iran war and the damage to the global supply chain created an expectation for even higher oil prices in the summer. 

HIP-3 trading shifted to oil futures, displacing silver and gold. | Source: Dune Analytics. In the past week, the XYZ:CL representing WTI oil entered the top 5 of the most traded futures. Oil displaced gold, silver, and copper as the previously hot-traded assets. 

Hyperliquid traders shift to commodities The XYZ:CL is the second most traded contract on HIP-3, while a new Brent contract has entered the top 10 and is climbing in open interest and volumes. The shift to commodities follows the most recent stagnation of crypto prices, as traders were in search of more active assets. 

Oil broke above $100 for the first time in years, as the situation in Iran grew more complicated. Brent crude traded above $106, and WTI climbed to over $109, with the potential to turn oil into a major crypto trade on Hyperliquid. As Cryptopolitan reported, oil had a historical week, displacing speculation on stocks. The hard factors behind oil appreciation allowed traders to take more directional bets in an otherwise risky and choppy market. 

The shift to oil arrived as BTC retreated to the $67,000 range, erasing the hopes of an easy rally. At the same time, oil shows no signs of stopping, expecting vertical expansion with Monday’s market opening.

Whales take large positions on oil futures While the biggest whales on Hyperliquid are still in crypto trades, the positions of whales on oil futures are growing. The influence of XYZ also grows, as it takes over 85% of Hyperliquid open interest, breaking above $1B in the past week. 

One of the early whales is holding a 2X leveraged position with a $6.3M notional value. 

A more aggressive trader has entered the market at $102 for WTI, with a position valued at over $14.9M and 20X leverage. The positions are relatively new, taken as oil on traditional markers broke above $100. Previous whales were already longing oil as the price broke above $90, showing that the more recent traders are ready to pay funding fees.

Oil remains risky as the price may be tamed by releasing reserves. However, the disruptions of war may prove the more influential factor, while whales are also feeling a sense of urgency in trading on HIP-3. 

Historically, expensive oil has put a damper on the crypto market. The existing infrastructure for oil trades also meant whales were ready to switch seamlessly. For now, the traders try to take profits in case the oil rally stalls temporarily.

Bitcoin USD Dominance Drops to 58%: Smart Capital Rotating Into Ethereum? Ethereum (ETH)

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

David Pokima

Author

David Pokima

Part of the Team Since

Jun 2023

About Author

David is a finance journalist and a contributor to Cryptonews.com with a keen interest in breaking comprehensive, accurate, and reliable blockchain news.

Has Also Written

Fact Checked by

CryptoNews Editorial Team

Author

CryptoNews Editorial Team

Part of the Team Since

Sep 2018

About Author

The CryptoNews editorial team is composed of seasoned writers specializing in cryptocurrency and blockchain technology. Their expertise ensures comprehensive, accurate, and insightful content for...

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

14 minutes ago

Bitcoin USD continues to hover near $67,200 following a week of tight-ranging price action. However, its longstanding dominance over the broader cryptocurrency market is visibly softening today.

Fresh data from CoinGecko reveals the total cryptocurrency market capitalization expanding past $2.38 trillion, while Bitcoin Dominance has fallen below 59% and is currently sitting at 58.82%.

SOURCE: CoinGeckoThat steady retreat coincides with a sudden burst of momentum in Ethereum, up +1.1% overnight and into this Monday morning trading session, while BTC grinds sideways on lower volume.

The underlying shift in data suggests institutional money might be preparing for a massive crypto capital rotation, which could signal the start of an alt season.

SOURCE: TradingViewWhat the On-Chain Dominance Drop Actually ShowsMarket dominance dropping back to 58.48% represents a notable cooling off from the stubborn mid-2025 peaks, where Bitcoin controlled nearly 66% of all crypto investor wealth.

Tom Lee, the chair of Ethereum Treasury firm Bitmine, recently noted that this gradual market compression will eventually trigger a violent V-shaped recovery in the heavily scrutinized ETH/BTC pair.

Current exchange flow metrics support the thesis that liquidity is merely shifting ecosystems rather than exiting the crypto market entirely. Nearly $31.6M worth of ETH left centralized exchanges in a single day recently, artificially tightening secondary supply right as dominance numbers dipped.

That is the exact type of localized supply shock that typically precedes a substantial decoupling phase in Ethereum. But the picture is not completely flawless for altcoin bulls.

Analysts like Kyle Reidhead argue the on-chain migration of traditional assets absolutely favors Ethereum, but excessively high funding rates suggest retail long positions are still too numerous, hinting that the bottom may not yet be in.

Discover: The best crypto to buy now

Bitcoin USD Price Prediction: Can BTC Hold $67,000 While Dominance Fades? BITCOIN IS TESTING THE LEVEL THAT STARTED THE LAST RALLY.

In 2023 the 200 EMA acted as the launchpad for the entire move.

Price reclaimed it.
Retested it.
Then exploded higher.$BTC is now back at the same structure near $65K.

Hold it and continuation follows.
Lose it… and… pic.twitter.com/DIMAWzxGss

— Merlijn The Trader (@MerlijnTrader) March 8, 2026 Bitcoin USD is consolidating between $64,000 and $72,000, creating an extended, choppy range that is slowly bleeding active volume from the primary asset. Even with aggregate reserves clearly vanishing from spot exchanges, sparking fierce debate among traders over whether a massive supply shock is coming.

If the current technical channel support resting at $66,500 holds steady, BTC could still muster enough localized liquidity to forcefully retest the $70,000 psychological barrier.

But if that floor fails under the heavy weight of altcoin rotations, the market structure weakens rapidly. In that bearish scenario, $64,000 becomes the immediate short target, followed closely by deeper institutional demand zones lurking near $61,000.

The definitive level to watch closely is exactly 58% on the dominance metric chart, which could ultimately dictate whether average BTC prices break out or break down completely.

Ethereum ETF Inflows Challenge Bitcoin’s Liquidity Monopoly SOURCE: TradingView Institutional interest in Ethereum is growing, with rising market metrics indicating increased ETF inflows. Last week closed with around +$20M in positive flows across the numerous ETH ETF products, with BlackRock, Grayscale, and Fidelity accounting for most of the volume, per CoinGlass data.

Analysts at FalconX note that Ethereum’s technological advantages in tokenized assets and its yield-bearing opportunities are attracting new investments that might have previously gone to Bitcoin USD ETFs.

For a confirmed decoupling, the ETH/BTC pair needs to rise above the 0.035 level on high volume, with it currently trading at 0.02939. If whales can regain the crucial $2,000 support, bullish momentum may build.

However, if the ratio fails to break 0.035 and $2,000 can’t be reclaimed, this could merely be a temporary trend, with support at $1,800 then becoming a likely target.

Discover: The top crypto to diversify your portfolio with

Key Takeaways While Bitcoin’s correlation coefficient with the S&P 500 and Nasdaq has climbed to approximately 0.5, equity market dynamics explain just 25% of price fluctuations Crypto-native elements including ETF inflows, derivative activity, and blockchain metrics account for the remaining 75% of Bitcoin’s valuation changes According to NYDIG’s research director, these findings validate Bitcoin’s continued function as a diversification tool The conversation around Bitcoin has evolved from questioning its viability to discussing its potential as a government reserve holding NYDIG maintains that Bitcoin’s expansion trajectory doesn’t require validation through central bank reserves Despite Bitcoin’s increasing synchronization with technology equities, the digital asset maintains its portfolio diversification characteristics, according to analysis from investment research firm NYDIG.

In a recently released market commentary, Greg Cipolaro, serving as NYDIG’s global head of research, noted that correlation metrics between Bitcoin and prominent U.S. stock indices have strengthened over recent months. The S&P 500 index, Nasdaq 100, and the software-focused IGV ETF have all demonstrated tighter price synchronization with Bitcoin.

Source: NYDIG Certain financial observers have interpreted this pattern as evidence that Bitcoin now functions essentially as a proxy for technology sector exposure. Cipolaro challenges this interpretation.

Despite the 90-day rolling correlation hovering around 0.5, Cipolaro emphasizes that this metric indicates equity market activity drives only roughly 25% of Bitcoin’s price volatility. The other 75% stems from dynamics unique to cryptocurrency markets.

These cryptocurrency-specific drivers encompass investment flows into Bitcoin exchange-traded products, changes in futures and options positioning, blockchain network growth metrics, and policy developments.

The Case for Bitcoin’s Distinct Market Behavior According to Cipolaro, the current price correlation between Bitcoin and growth-oriented equities probably mirrors prevailing macroeconomic conditions rather than indicating a fundamental structural connection. Both asset classes simultaneously react to changes in market liquidity and investor willingness to assume risk.

“Cross-asset correlations with equities are currently elevated, but they remain far from determinative of Bitcoin’s returns,” Cipolaro wrote.

The NYDIG analysis also referenced recent public statements from well-known investors. Chamath Palihapitiya, who famously dubbed Bitcoin “Gold 2.0” back in 2013, has recently expressed skepticism about the asset’s suitability for sovereign treasury holdings. Ray Dalio has consistently voiced reservations regarding Bitcoin’s price volatility, regulatory uncertainty, and potential future vulnerabilities from quantum computing breakthroughs.

Cipolaro interprets these critiques as evidence of Bitcoin’s evolution rather than indicating fundamental problems. The discussion has shifted from questioning Bitcoin’s basic viability to debating whether monetary authorities should include it in reserve portfolios.

Central Bank Adoption Not Essential for Bitcoin Development NYDIG’s position is that government and central bank adoption isn’t a necessary condition for Bitcoin’s continued expansion. The network has already achieved significant penetration beyond individual retail participants, extending to high-net-worth family offices, institutional money managers, and publicly traded investment vehicles.

This adoption trajectory differs markedly from typical financial innovation patterns, which usually begin with institutional capital before filtering down to individual investors. Bitcoin has taken the reverse path.

“Central bank ownership may ultimately validate the asset class further, but it is not a prerequisite for continued growth,” Cipolaro wrote.

NYDIG’s analysis emphasized Bitcoin’s fundamental characteristics: a decentralized global network infrastructure, political independence, and technical architecture enabling censorship-resistant value transmission and programmatic scarcity outside the control of any governmental or monetary institution.

Bitcoin was trading at approximately $67,769 when the report was published.

TLDR ADA currently trading in the $0.25–$0.257 range, reflecting a nearly 9% decline across the past seven days Derivatives open interest climbed 3.87% reaching $428.45 million, while trading volume jumped 33.39% to $779.84 million On-chain metrics show daily active addresses declining since end of January, currently at 13.5K March 8 announcement from Cardano Foundation confirmed successful Archax integration, a UK FCA-regulated platform Critical resistance zone located at $0.2614 (Fibonacci 0.5 level); breakthrough could push price toward $0.2826 Cardano (ADA) is currently changing hands at approximately $0.2572 as of Monday, showing modest recovery following a challenging seven-day period that witnessed close to a 9% decline. The cryptocurrency continues trading beneath both its 50-day and 100-day moving averages, reinforcing the prevailing bearish sentiment.

[[IMG_2]]Cardano (ADA) Price Derivatives data reveals open interest has increased by 3.87% to reach $428.45 million, while trading volume experienced a significant 33.39% surge to $779.84 million. This notable volume expansion arrived on the heels of announcements regarding Cardano’s collaboration with Archax, a digital exchange operating under UK Financial Conduct Authority regulation.

[[IMG_3]]Source: Coinglass Binance’s long/short ratio indicates 1.81 for general accounts and 1.94 among elite traders, demonstrating that leveraged market participants are positioning themselves bullishly. Total liquidation figures reached $183.61K, with short position liquidations accounting for $180.90K of the total.

While short-term volume metrics appear encouraging, blockchain activity data presents a more reserved outlook. Daily active addresses have experienced consistent downward movement since the conclusion of January, currently registering at 13.5K. A declining active address count typically signals reduced network demand.

Archax Integration Opens Institutional Door The March 8 announcement from Cardano Foundation CEO Frederik Gregaard verified the successful integration of Cardano into Archax’s platform. Archax maintains operations under UK FCA supervision while adhering to European Union regulatory standards.

Cardano is now integrated into @ArchaxEx’s tokenization engine, a next milestone for Cardano’s institutional infrastructure.

This means:
∙ All Cardano based MembersCap’s Fund I tokens (MCM tokens) now sit within Archax’s regulated infrastructure

∙ Straightforward tokenization… pic.twitter.com/evirPuz5Nr

— Cardano Foundation (@Cardano_CF) March 6, 2026

This collaboration enables MemberCaps Fund I tokens to exist within Archax’s regulated framework. Any assets tokenized through Archax on the Cardano network will face rigorous financial oversight from inception.

Gregaard characterized the partnership as “a tough one” to finalize. The arrangement provides institutional investors with a compliant channel for tokenizing conventional assets — including real estate and securities — utilizing the Cardano blockchain infrastructure.

Technical Levels to Watch Examining the 4-hour timeframe, ADA is currently challenging the Fibonacci 0.5 retracement level positioned at $0.2614. Four exponential moving averages are clustering between $0.2574 and $0.2699, creating a significant resistance barrier that must be overcome.

[[IMG_4]]Source: TradingView An ascending trendline provides support around $0.2458. Should that level fail, the $0.25–$0.24 area represents the subsequent structural support zone.

Upside resistance beyond $0.2614 extends toward the Fibonacci 0.382 level at $0.2826, followed by the descending channel’s upper boundary ranging between $0.29 and $0.31.

The Relative Strength Index registers at 41 on the daily timeframe, indicating diminished momentum. The MACD indicator remains close to the zero line, aligning with a moderately bearish outlook.

A daily candle close surpassing $0.27–$0.28 would be required to alter the technical landscape favorably. While price remains below $0.27, sellers maintain their structural advantage.

As of March 9, ADA continues consolidating near $0.2572 following confirmation of the Archax partnership, with derivatives metrics indicating renewed capital allocation into long positions.